Fuan Pharmaceutical Group Co Ltd is a China-based company primarily engaged in the research and development, production and sales of pharmaceutical products. The Companyâ€™s main business includes research and development of pharmaceutical products and production and sales of pharmaceutical intermediates, chemical active pharmaceutical ingredients and preparations. The Companyâ€™s products include antibiotics, anti-tumor, specialty medicines and other categories of medicines. The Companyâ€™s other business includes medicine distribution and other businesses. The Company operates its business in the domestic and overseas markets.

Employees

2,988

Sector

Pharmaceuticals

Calendar

Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
26-07-07	CN¥3.550	-3.53%	14,857,100
26-07-06	CN¥3.680	+1.10%	19,549,100
26-07-03	CN¥3.640	+1.68%	18,077,245
26-07-02	CN¥3.580	+1.70%	22,977,934
26-07-01	CN¥3.520	+4.14%	19,471,539

End-of-day quote Shenzhen S.E.

More quotes

Income Statement and Estimates

More financial data

Annual profits - Rate of surprise

Company calendar

End-of-day quote Shenzhen S.E. Other stock markets 2026-07-07			5-day change	1st Jan Change
3.550 ^CNY	-3.53%		+2.60%	-19.86%

05-22	Fuan Pharmaceutical Subsidiary Gets China Approval for Three Injectable Drugs	MT
05-21	Fuan Pharmaceutical Co., Ltd. Announces Final Cash Dividend on A Shares for the Year 2025, Payable on 28 May 2026	CI

Market Cap	4.22B 622M 544M 501M 465M 882M 58.99B 896M 6.01B 2.34B 29.11B 2.33B 2.28B 101B	P/E 2024	18.6x	P/E 2025	73.8x
Enterprise Value	3.99B 587M 513M 473M 439M 833M 55.69B 846M 5.67B 2.21B 27.49B 2.2B 2.16B 95B	EV / Sales 2024	2.15x	EV / Sales 2025	2.9x
Free-Float	68.44%	Yield 2024	1.12%	Yield 2025	1.58%

05-22	Fuan Pharmaceutical Subsidiary Gets China Approval for Three Injectable Drugs	MT
05-21	Fuan Pharmaceutical Co., Ltd. Announces Final Cash Dividend on A Shares for the Year 2025, Payable on 28 May 2026	CI
04-26	Fuan Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
04-26	Fuan Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
11-05	Fuan Pharmaceutical Gets Philippines Good Manufacturing Practice Nod for Antibiotic Production	MT
25-10-27	Fuan Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025	CI
25-09-21	Fuan Pharmaceutical Co., Ltd.(XSEC:300194) added to S&P Global BMI Index	CI
25-09-16	Fuan Pharmaceutical Co., Ltd. Approves Interim Cash Dividend for 2025 on A Shares, Payable on 25 September 2025	CI
25-08-27	Fuan Pharmaceutical Co., Ltd. Proposes Interim Cash Dividend for 2025	CI
25-08-26	Fuan Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
25-05-16	Fuan Pharmaceutical Co., Ltd. Approves Final Cash Dividend (A Shares) for the Year 2024, Payable on 28 May 2025	CI
25-04-24	Fuan Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for the Year 2024	CI
25-04-23	Fuan Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI

1 day	-3.53%
1 week	+2.60%
Current month	+5.03%
1 month	-4.83%
3 months	-14.66%
6 months	-21.29%
Current year	-19.86%

Fuan Pharmaceutical (Group) Co., Ltd. Stock

Stocks

300194

CNE1000011G4

Pharmaceuticals

Valuation: Fuan Pharmaceutical (Group) Co., Ltd.

Chart: Fuan Pharmaceutical (Group) Co., Ltd.

Latest news : Fuan Pharmaceutical (Group) Co., Ltd.

Quotes and Performance

Course Extremes

Managers and Directors: Fuan Pharmaceutical (Group) Co., Ltd.

Latest insider transactions

Generic Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

1 week	3.35	3.72
1 month	3.24	3.72
Current year	3.24	4.75
1 year	3.24	5.48
3 years	2.92	5.68
5 years	2.92	5.68
10 years	2.87	11.51

Manager	Title	Age	Since
Lu Wang CEO	Chief Executive Officer	42	2023-12-03
Xue Song Yu DFI	Director of Finance/CFO	57	2009-09-18
Qin Tang SEC	Corporate Secretary	57	2009-09-18

Director	Title	Age	Since
Tian Xiang Wang CHM	Chairman	70	2009-09-18
Qin Tang BRD	Director/Board Member	57	2009-09-18
Xue Song Yu BRD	Director/Board Member	57	2018-12-20

Date	Insider	Type	Main position	Quantity	% Market Cap.
20-01-06	Tao Huang	Sell	Director	3,000,000	0.3361%
20-01-01	Tao Huang	Sell	Director	1,558,500	0.1746%
20-01-01	Jing Feng	Sell	Executive/Senior Manager	30,300	0.0034%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
FUAN PHARMACEUTICAL (GROUP) CO., LTD.	-3.53%	+2.60%	-18.58%	-8.97%	644M
SUN PHARMACEUTICAL INDUSTRIES LTD.	-0.49%	+1.53%	+13.55%	+82.58%	48.11B
OTSUKA HOLDINGS CO., LTD.	-1.13%	+5.37%	+69.14%	+118.27%	37.88B
CIPLA LIMITED	-1.39%	-0.16%	-4.06%	+42.16%	12.47B
ZYDUS LIFESCIENCES LIMITED	+0.44%	+2.83%	+15.18%	+96.06%	12B
KRKA, D. D.	+0.38%	+2.76%	+34.19%	+120.25%	9.03B
GEDEON RICHTER	-0.16%	+1.91%	+22.31%	+47.95%	7.24B
ONO PHARMACEUTICAL CO., LTD.	+0.43%	+3.39%	+56.76%	-2.30%	7.09B
GLENMARK PHARMACEUTICALS LIMITED	-0.26%	+3.58%	+23.74%	+238.93%	6.72B
SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.	-2.81%	+17.66%	-18.38%	+20.93%	6.54B
Average	-0.85%	+3.83%	+19.38%	+75.59%	14.77B
Weighted average by Cap.	-0.65%	+3.96%	+29.13%	+89.93%

	2024	2025
Net sales	2.39B 352M 308M 284M 263M 499M 33.4B 507M 3.4B 1.32B 16.48B 1.32B 1.29B 56.98B	1.74B 256M 224M 206M 191M 363M 24.28B 369M 2.47B 962M 11.98B 960M 940M 41.42B
Net income	280M 41.18M 36.04M 33.21M 30.78M 58.44M 3.91B 59.38M 398M 155M 1.93B 155M 151M 6.67B	77M 11.33M 9.92M 9.14M 8.47M 16.08M 1.08B 16.34M 110M 42.61M 531M 42.54M 41.62M 1.83B
Net Debt	-171M -25.1M -21.96M -20.24M -18.76M -35.62M -2.38B -36.19M -243M -94.39M -1.18B -94.23M -92.19M -4.06B	-236M -34.77M -30.42M -28.04M -25.99M -49.34M -3.3B -50.13M -336M -131M -1.63B -131M -128M -5.63B